Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  ATX-304 (Pan-AMPK Activator)

Research reference — not for sale

ATX-304 (Pan-AMPK Activator)

D

lead outcome

Metabolic / fat-loss benefit as a supplement…

grades vary by outcome ↓

Small molecule (non-peptide)

also called — ATX-304 · pan-AMPK activator (direct) · (marketed in some blends as "OS-01" — a name also used unrelatedly for a cosmetic peptide; see identity)

systemic / metabolic (reference)AMPK activatorNOT cosmeticNOT topical

Safety

ATX-304 is an investigational clinical-stage compound, not an approved supplement or cosmetic. Its safety and efficacy as a self-administered metabolic supplement are not established, and AMPK activation has broad, systemic downstream effects. Metabolic and weight concerns should be handled with a doctor rather than a gray-market research compound.

In brief

ATX-304 is a direct pan-AMPK activator — it switches on AMP-activated protein kinase, the cell's central energy sensor, turning up fat-burning and glucose uptake and turning down fat synthesis, the same master pathway that metformin hits indirectly and exercise engages. It is a genuine clinical-stage metabolic compound with real preclinical data. The honest calibration: its use as a self-administered "metabolic optimiser" supplement runs ahead of published controlled human efficacy and safety evidence for that purpose, and AMPK is a pleiotropic master switch whose pharmacological activation needs clinical data to judge. A naming note: some blends label it "OS-01," a tag also used unrelatedly for a cosmetic peptide — they are not the same thing. ATX-304 is a research compound, not a cosmetic, drug or proven supplement.

Legal standing, by region

International

Clinical-stage research compound (not a cosmetic, not an approved consumer product)

ATX-304 is an investigational compound, not an approved medicine, supplement or cosmetic, and has no topical use. It appears in this register only because it is scanned/searched from the research-compound and fat-loss gray market. Rules vary by jurisdiction.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Metabolic / fat-loss benefit as a supplement (the marketed use)

Clinical-stage development is not the same as a validated over-the-counter supplement; dosing and safety outside a trial are unestablished.

ATX-304 is a genuine clinical-stage direct AMPK activator with real preclinical metabolic data, but its use as a self-administered "metabolic" supplement is ahead of published controlled human efficacy/safety evidence for that purpose. · Not established as a consumer supplement.

D

Direct AMPK activation (mechanism)

Grades the MECHANISM. AMPK is a pleiotropic master switch; activating it pharmacologically has broad downstream effects that require clinical data to judge.

Well-described: ATX-304 directly activates AMP-activated protein kinase (AMPK), the cell's central energy sensor, switching on fatty-acid oxidation and glucose uptake and switching off lipogenesis — the same master pathway targeted by metformin (indirectly) and exercise. · A real, well-characterised metabolic mechanism.

C

"Exercise mimetic / metabolic optimiser" framing

Shares the "exercise-in-a-pill" framing of the ERR agonists and metabolic peptides; the human evidence for that consumer claim is not established.

Marketing/forum claim

D

Safety / status

Sold research-use-only / in gray-market blends; no established supplement dosing or safety profile.

Clinical-stage research compound; no approved consumer use · Human safety outside trials unestablished

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for ATX-304 (Pan-AMPK Activator) changes - nothing else.

Identity

ATX-304 is a synthetic direct pan-AMPK activator — a clinical-stage metabolic research compound, not a peptide, cosmetic or supplement. It appears in this register because the fat-loss and longevity gray market sells it (including in capsule "metabolic" blends), and people scan and search it.

A naming warning: some blends label ATX-304 as "OS-01." That same tag is used, unrelatedly, for a cosmetic peptide in the skincare world. They are different substances, and conflating them is an error to guard against — this entry is the metabolic AMPK activator, not the cosmetic peptide.

Mechanism (as proposed)

AMPK (AMP-activated protein kinase) is the cell's central energy sensor: when energy runs low it switches the cell toward burning fuel — fatty-acid oxidation, glucose uptake — and away from storing it (lipogenesis). It is the master pathway that exercise engages and that metformin activates indirectly. ATX-304 activates AMPK directly, which is the basis of its metabolic-disease rationale. The mechanism is genuine and well characterised. The honest limit is breadth: AMPK is a pleiotropic master switch, so activating it pharmacologically has wide downstream effects that only clinical data can properly weigh.

Reading the evidence honestly

ATX-304 is further along than many gray-market compounds — it is clinical-stage, with real preclinical metabolic data. But its use as a self-administered "metabolic optimiser" supplement runs ahead of published controlled human efficacy and safety evidence for that consumer purpose, which is why it grades D. It shares the "exercise-in-a-pill" framing of the ERR agonists (SLU-PP-332) and other metabolic modulators — a framing this register consistently flags as running ahead of the human evidence. It is a research compound, not a cosmetic, drug or proven supplement, and metabolic concerns belong with a doctor.

Sources — 2 cited

01Preclinical and clinical-stage literature on ATX-304 as a direct pan-AMPK activator for metabolic disease.

02Reviews of AMPK as a metabolic master switch and of direct AMPK-activator pharmacology.

Updated 2026-08-07

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

SLU-PP-332 (ERR agonist / "exercise mimetic")F

Small molecule (non-peptide)

AICAR (Acadesine)F

Small molecule (non-peptide)

5-Amino-1MQ (NNMT inhibitor)F

Small molecule (non-peptide)

BAM15 (Mitochondrial Uncoupler)D

Small molecule (non-peptide)

Explore by goal

Metabolic →Mitochondrial →

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.